3R Pharma is on a mission to unlock and exploit the potential of cannabinoid-based medicines for serious ophthalmic conditions, that currently have limited or no treatment options. In order to provide an effective solution to ocular health issues, 3R Pharma is developing a patented ocular treatment method using cannabinoid-based formulations.
Chronic ocular surface diseases affect between 15-20% of the global population. For most of these chronic ailments, there are no long-term treatments, no FDA-approved protocols while exiting antibiotics or steroids can not be used continuously without significant side effects.
We have partnered with CanNegev Incubator that was established as a joint venture of Perrigo/Padagis, BOL Pharma, OurCrowd, and Israeli Innovation Authority, and received seed funding from the Israeli Innovation Authority to initiate our research.